New combo therapy aims to shrink tumors before stomach cancer surgery
NCT ID NCT07325630
Summary
This study is testing whether adding an experimental drug called IBI363 to standard chemotherapy helps people with a specific type of locally advanced stomach cancer. The goal is to shrink the tumor before surgery and control the disease afterward. The study will enroll 60 adults who have not had prior cancer treatment for this disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IBI363 + CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact
Conditions
Explore the condition pages connected to this study.